Sinopharm mulls $1B buyout of China-based DNA synthesis company — report

Nicole DeFeudis

Editor

After spending the last couple of years laser-focused on its inactivated Covid-19 vaccine, Sinopharm is reportedly in the market to expand its DNA synthesis capabilities …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sinopharm mulls $1B buyout of China-based DNA synthesis company — report

Nicole DeFeudis

Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Sinopharm mulls $1B buy­out of Chi­na-based DNA syn­the­sis com­pa­ny — re­port

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sinopharm mulls $1B buyout of China-based DNA synthesis company — report

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life